Alzamend Neuro Phase 1/2A AL001 lithium imaging data wins oral slot at ISMRM X-Nuclei MR workshop

ALZN•2026-08-18

AL001 imaging data selected for oral presentation

Alzamend Neuro flagged Phase 1/2A brain-imaging results for AL001, its organic lithium candidate, slated for an ISMRM workshop oral talk.

Data will be presented September 29, 2026 in Barcelona, covering how AL001 distributes in brain tissue over time in healthy subjects.

Acceptance for an oral session signals external scientific vetting, supporting the program’s clinical positioning for better-tolerated lithium therapy.

Alzamend Neuro Phase 1/2A AL001 lithium imaging data wins oral slot at ISMRM X-Nuclei MR workshop

AL001 imaging data selected for oral presentation

Related News

Einride CEO expects fleet to reach just under 400 trucks by year-end, driven by Amazon deployments and initial Tesla Semi rollout

Standardaero To Continue U.S. Air Force T56 Engine Depot Maintenance Support For C-130 Aircraft Globally

Norwegian Cruise Line falls as Mizuho downgrades stock to 'neutral'

Voya wins District of Columbia contract to service $4.3 billion retirement plans

Table-U.S. July housing starts fall 12.4%